Evaluation of safety and pharmacokinetics of bismuth‐containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication

• Published in: British journal of clinical pharmacology Vol. 88; no. 1; pp. 138 - 144
• Main Authors: Huh, Ki Young, Chung, Hyewon, Kim, Yu Kyong, Lee, SeungHwan, Bhatia, Siddharth, Takanami, Yohei, Nakaya, Ryou, Yu, Kyung‐Sang
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 01.01.2022
• Subjects: Amoxicillin; Anti-Bacterial Agents; Bismuth - adverse effects; bismuth, drug interaction, Helicobacter pylori, quadruple therapy, vonoprazan; Clarithromycin - adverse effects; Drug Therapy, Combination; Helicobacter Infections - drug therapy; Helicobacter pylori; Humans; Lansoprazole - adverse effects; Original; Pyrroles; Sulfonamides; Treatment Outcome; bismuth, drug interaction, Helicobacter pylori, quadruple therapy, vonoprazan

Aims Helicobacter pylori (Hp) eradication plays a key role in the treatment and prevention of peptic ulcer diseases. Increasing clarithromycin resistance in Hp necessitates more effective treatments for eradication, such as bismuth‐containing quadruple therapy. We aimed to compare the safety and pha...